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Abstract
Background
The search for diagnostic biomarkers has been profiting from a growing number of high
quality sequenced genomes and freely available bioinformatic tools. These can be com-
bined with wet lab experiments for a rational search. Improved, point-of-care diagnostic
tests for visceral leishmaniasis (VL), early case detection and surveillance are required. Pre-
vious investigations demonstrated the potential of IgG1 as a biomarker for monitoring clini-
cal status in rapid diagnostic tests (RDTs), although using a crude lysate antigen (CLA) as
capturing antigen. Replacing the CLA by specific antigens would lead to more robust RDTs.
Methodology
Immunoblots revealed L. donovani protein bands detected by IgG1 from VL patients. Upon
confident identification of these antigens by mass spectrometry (MS), we searched for
evidence of constitutive protein expression and presence of antigenic domains or high
accessibility to B-cells. Selected candidates had their linear epitopes mapped with in silico
algorithms. Multiple high-scoring predicted epitopes from the shortlisted proteins were
screened in peptide arrays. The most promising candidate was tested in RDT prototypes
using VL and nonendemic healthy control (NEHC) patient sera.
Results
Over 90% of the proteins identified from the immunoblots did not satisfy the selection criteria
and were excluded from the downstream epitope mapping. Screening of predicted epitope
peptides from the shortlisted proteins identified the most reactive, for which the sensitivity
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for IgG1 was 84% (95% CI 60—97%) with Sudanese VL sera on RDT prototypes. None of
the sera from NEHCs were positive.
Conclusion
We employed in silico searches to reduce drastically the output of wet lab experiments,
focusing on promising candidates containing selected protein features. By predicting epi-
topes in silico we screened a large number of peptides using arrays, identifying the most
promising one, for which IgG1 sensitivity and specificity, with limited sample size, supported
this proof of concept strategy for diagnostics discovery, which can be applied to the develop-
ment of more robust IgG1 RDTs for monitoring clinical status in VL.
Author summary
Visceral leishmaniasis (VL) is a neglected tropical disease caused by protozoan parasites
of the Leishmania donovani complex. Without treatment, VL is fatal. Although diagnostic
techniques, mainly based on the detection of anti-Leishmania antibodies are available,
invasive procedures such as microscopy from spleen or bone marrow aspirates are still
required for the diagnosis of seronegative VL suspects, for the detection of recurrent cases
and to confirm cure after successful treatment. Previous investigations showed the poten-
tial of IgG1 as a biomarker of post-chemotherapeutic relapse for VL in rapid diagnostic
tests (RDTs) sensitised with crude lysate antigen (CLA). Here we employed in silico tools
to search for desired protein features in a large number of L. donovani antigens detected
by human IgG1 in western blots. We then employed prediction algorithms to profile epi-
topes from the shortlisted proteins. We screened a panel of high-scoring peptides in a
high-throughput manner using arrays, with low reagent consumption. The most reactive
peptide was adapted to RDTs, showing promising results of both sensitivity and specific-
ity. This peptide has the potential of replacing the CLAs in IgG1 RDTs. Thus we believe
that in silico tools can be used to optimise wet lab experiments for a rational search of
biomarkers.
Introduction
The leishmaniases comprise a group of vector-borne diseases caused by parasites of the genus
Leishmania. The visceral form—visceral leishmaniasis (VL), also known as kala-azar (Hindi
for ‘black fever’) affects internal organs such as liver, spleen and bone marrow, and leads to
death if left untreated. VL is caused by parasites of the Leishmania donovani complex and in
2015 over 23.000 new cases were reported to the world health organization (WHO) worldwide
[1] while an overall case-fatality rate of 10% has been estimated [2]. VL is diagnosed by a com-
bination of clinical symptoms, including prolonged fever, weight loss, hepatosplenomegaly
and malaise, and the detection of parasite-specific immunoglobulins (Igs). The recombinant
protein rK39, a fragment of a Leishmania infantum kinesin-like gene, was described in 1993
[3] and remains the most widely used antigen for VL serodiagnosis. Nonetheless, novel and
improved antigens are still required to complement the use of the rK39, to improve sensitivity
in eastern Africa [4, 5] and to determine cure after successful chemotherapy (versus relapse).
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The recombinant chimeric protein rK28, which is a derivative of the rK39, incorporating
the first two repeats of a Sudanese L. donovani kinesin flanked by proteins HASPB1 and
HASPB2, was engineered to address low sensitivity values reported from eastern Africa.
Although a slight better performance compared to the rK39, both in terms of sensitivity and
specificity, was reported with Sudanese VL patients [6], important variations in sensitivity
amongst different rK39 rapid diagnostic test (RDT) manufacturers were also reported from
that region [7]. Moreover, false positive rates as high as 19.5% in eastern African patients were
described [8], meaning that further investigations are still required to confirm the relevance of
the rK28 as well as its superiority over the rK39-based diagnostic tests for VL in eastern Afri-
can patients. Due to Igs persistence even after complete parasite clearance [9–13], neither the
rK39 nor the rK28 commercial diagnostic kits can be employed to determine cure after suc-
cessful chemotherapy.
There has been a dramatic reduction in genome sequencing costs, accompanied by an
exponential increase in the number of available sequences in public repositories [14, 15]. The
first Leishmania spp. genome sequencing was completed in 2005 [16]. More recently, the
advent of high-throughput technologies has enabled the completion of the whole genome
sequencing of L. donovani, the causative agent of VL in the Indian subcontinent [17]. More-
over, the availability of next-generation sequencing made it possible to perform whole tran-
scriptome sequencing. RNA sequencing (RNA-seq) generates data on the transcriptome at a
specific stage of a pathogen life cycle or in a specific culture condition of an organism. The
growing number of available, high quality, whole genome sequences has become a central ele-
ment in the area of comparative genomics, which has contributed greatly to a better under-
standing of multiple aspects of the leishmaniases, including determinants of disease phenotype
[18], mode of action of drugs [19] and parasite biology [20].
Igs are a major component of the immune system. They bind specific regions of pathogens’
proteins (epitopes), tagging them for clearance by the immune system. Epitopes can be divided
into linear (a continuous stretch of amino acids (AAs)) and discontinuous (where non-proxi-
mal residues are brought together by protein folding) and can be identified by functional and
structural studies (e.g. X-ray crystallography), while in silico epitope prediction algorithms are
gaining popularity. The early prediction methods of linear B-cell epitopes were mainly based
on propensity scales [21]. More recently, machine learning methods have been employed to
improve prediction performance [22–24]. The prediction of discontinuous epitopes still
depends on the availability of 3D structures. In silico tools can also be used to locate antigenic
domains from DNA sequences or peptide sequences influencing protein localisation within
cells.
Diagnostic research can incorporate genomics, transcriptomics, proteomics as well as bio-
informatic prediction algorithms for the discovery of new biomarkers. Such a systematic
‘omics’ approach has been applied alone for the discovery of vaccine candidates [25–27] as
well as for diagnostic biomarkers [28]. These in silico searches can also be applied downstream
of wet lab experiments, refining their output for a rationalised search.
Mass spectrometry (MS) can be used to identify proteins from wet lab experiments (e.g.
immunoblots). Comparative genomics enables identification of species-specific genes, while
levels of life-stage specific proteins can be estimated using publicly available RNA-seq data. In
silico prediction algorithms can be employed to infer protein localisation, search for antigenic
domains as well as to predict linear B-cell epitopes. Synthetic peptides can then be incorpo-
rated into arrays, enabling the screening of a large number of candidates in pilot serological
assays. Promising candidates can be adapted and tested in RDTs, a format suitable for field
use.
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Here we employed comparative genomics as well as in silico algorithms to reduce drastically
the excessive number of L. donovani protein candidates recognised by human IgG1, which has
been shown to be a potential indicator of post-chemotherapeutic relapse in VL, using RDT
prototypes sensitised with a L. donovani crude lysate antigen (CLA) [29]. By screening a large
number of predicted epitopes from selected candidate antigens containing desired protein fea-
tures, we identified one peptide specifically recognised by IgG1 in arrays. This peptide was also
tested in prototype RDTs with VL patient sera as well as sera from nonendemic healthy con-
trols (NEHCs), showing promising results of both sensitivity and specificity on a small sample
size. Thus we propose that this approach is a valid proof of concept for the discovery of diag-
nostic peptides, which can be used to replace the CLA in IgG1 RDTs, leading to the production
of cheaper and more robust RDTs for monitoring clinical status in VL.
Methods
Ethics statement
In India, the collection of samples was approved by the Ethics Committee of Banaras Hindu
University, Varanasi while in Sudan the approval for collection and research was granted by
the Ethical Research Committee, Faculty of Medicine, University of Khartoum and the
National Health Research Ethics Committee, Federal Ministry of Health, Sudan. Written
informed consent was obtained from all adult subjects included in the study or from the
parents or guardians of individuals less than 18 years of age. This research was also approved,
as part of the EC NIDIAG project, by the London School of Hygiene and Tropical Medicine
Ethics Committee as well as by the Ethics Committee of the Antwerp University Hospital.
Sources of sera
A detailed description of all serum samples used in this work can be found below while a sum-
mary is shown in Table 1.
India. Indian sera were selected from archived samples, collected after 2007 from active
VL, relapsed and endemic healthy controls (EHCs), all from the endemic region of Muzaffar-
pur, Bihar. Active VL cases had been diagnosed by positive rK39 and/or DAT serology and
parasitologically by microscopy of splenic aspirates prior to the present study. Relapses were
diagnosed clinically. All Indian samples were HIV negative.
Sudan. Sudanese serum samples were collected in 2011 and 2012 from the VL-endemic
region of Gedaref in eastern Sudan. VL cases had been diagnosed by microscopy of bone mar-
row or lymph node aspirates in conjunction with serological assays (rK39 or rK28) and were
all HIV negative. These diagnoses were carried out according to their respective national pro-
cedures, prior to the present study.
Table 1. Serum samples used in this study. Details of all serum samples used in the western blots, peptide arrays and
RDT prototypes.
Sample
type
Region Definitions n
Active VL India Samples were taken at or around onset of treatment (D0, D7 or D15) 25
Relapse VL treated and subsequently relapsed to active disease. Sampled at the time of relapse
diagnosis
26
Total India 51
Active VL Sudan Samples were taken at or around onset of treatment (D0, D7 or D15) 19
NEHC France Samples from healthy donors living in region where no transmission of VL is
documented
10
https://doi.org/10.1371/journal.pntd.0007353.t001
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NEHC. Sera was obtained from whole blood collected from Etablissement Français du
Sang, France. All donors were informed of the use of the blood for research purpose and gave
their informed consent for the purpose of scientific research use and that all national laws and
ethical principles were fulfilled. The samples were fully anonymised. All samples were certified
to be negative for the following transmissible diseases: HIV-1, HIV-2, HCV, HBV, HTLV I,
HTLV II and syphilis.
Wet lab identification of L. donovani antigens detected by IgG1
L. donovani promastigote antigens recognised by human IgG1 were profiled using western
blots as described in the repository protocols.io (dx.doi.org/10.17504/protocols.io.u8rezv6).
Briefly, the cytosolic proteins from a L. donovani (strain MHOM/IN/80/DD8) whole cell
lysate were separated by SDS-PAGE, blotted onto a nitrocellulose (NC) membrane and sliced
into individual strips, to be immunoassayed with sera from individual patients from India.
Upon visual identification of bands of interest on the individual strips using HRP-labelled
anti-human IgG1 as secondary antibody, new gels were run and corresponding immuno-
genic bands were excised and analysed by mass spectrometry (MS) (syn. liquid chromatogra-
phy tandem mass spectrometry (LC-MS/MS)), according to the methods described in S1
Text. Protein hits were identified by matching peptide fragments against the L. donovani ref-
erence genome-derived proteome only (ENA accession nos. FR799588-FR799623 [17]),
henceforth referred to as LdBPK v1 genome. These proteins were submitted to the in silico
filter detailed below.
In silico refinement of wet lab output
Desired protein features were searched in silico in order to decrease the number of candidates
from the MS output while shortlisting the proteins more likely to be antigenic, to have their B-
cell epitopes mapped with in silico prediction algorithms. Some protein features were searched
in series while others in parallel, meaning that all shortlisted proteins satisfy the criteria
described in either branch as shown in Fig 1. These shortlisted v1 IDs were then merged with
the IDs from an improved LdBPK282 reference genome (ENA accession number ERP022358,
henceforth referred to as LdBPK v2) according to the correspondence in Data Set 2 from [30].
Hypothetical proteins were excluded, unless containing tandem repeats (TRs). Additional
information on each step of this in silico filter are detailed in the following subsections.
Gene expression analysis—RNA-seq. Transcriptomic data on seven promastigotes and
four amastigotes, representing different parasite life stages was obtained. In the present study
the improved LdBPK282 reference genome was used [30]. Leishmania chromosome copy
number is known to be variable, especially in cultivated promastigotes, which can potentially
change within a few passages. To quantify the RNA-seq depth levels, which were not affected
by somy variability, we used normalised haploid depth (HAP). The average normalised HAP
of all genes were ranked for promastigotes and amastigotes separately and only those genes
whose values were greater than the first quartile (HAP>Q1) in both parasite life stages were
considered as constitutively expressed and and kept for downstream analysis.
Confident MS identification. We matched the peptides identified by MS against the
LdBPK v1 genome only. Each protein hit identified by MS with the software MASCOT [31]
has its own score defined by:
MASCOT score ¼   10� log
10
ðPÞ
The score converted the probability that the observed match was not a random event (P) into
an ascending scale where the lowest score is the most unreliable match, and higher scores
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indicate more reliability [32]. A score of 100 was chosen as the cut-off value to minimise the
chances that any match could be found by chance.
Protein localisation. Exported L. donovani proteins, identified as part of exosomes by
experimental approaches [33] and/or by the presence of a signal peptide were considered
highly accessible to B-cells and thus selected for further analysis. The presence of a signal pep-
tide sequence was searched with the stand-alone version of the software SignalP v4.0 [34] with
the option ‘noTM’. All other optional parameters were default.
Antigenic domain selection. L. donovani proteins harbouring TRs include known B-cell
antigens such as rK39 and rK28, therefore the presence of this domain was included as a crite-
rion correlating with antigenicity. The protein coding DNA sequences were scanned for the
presence of TRs using the stand-alone version of the program Tandem Repeats Finder [35]
(v4.09). All program parameters were default.
Fig 1. In silico filter applied to select desired protein features. Selected protein properties (yellow and green nodes)
were searched in silico on all protein hits identified by MS from selected IgG1 sero-reactive western blot bands (MS
output—top node), with the ultimate goal of shortlisting protein candidates most likely to be antigenic (Shortlisted
proteins—bottom node).
https://doi.org/10.1371/journal.pntd.0007353.g001
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Epitope mapping from shortlisted proteins
Four in silico algorithms were used independently to define B-cell epitopes: ABCPred [23],
Bepipred1.0 [22], EpiQuest-B [36] and lbtope [37]. For all epitopes predicted from each algo-
rithm individually (generally a 15 or 16mer), a ‘core sequence’, stretching from the fifth to the
eleventh AA residue was defined and scanned against the rest of the predicted antigenic pep-
tides, in order to identify peptides of similar sequences. These peptides sharing core sequences
with other predicted peptides at any position in the AA sequence are henceforth referred as
partially overlapping peptides.
While ABCPred, lbtope and EpiQuest-B were run on default values, predicting antigenic
sequences of 16, 15 and 16 AA residues, respectively, shorter sequences with high antigenic
scores were also considered for EpiQuest-B. The highest scoring peptides predicted from
Bepipred were obtained by calculating the area under the curve (AUC) from plots of AA resi-
due position vs. individual residue score for all possible combinations of 16mers with one AA
offset, considering all contiguous predicted antigenic sequences from all submitted proteins.
Additional details about the prediction algorithms employed can be found in Table 2.
Peptide synthesis
Desalted peptides i.e. of varying purity grades were synthesised with an N-terminal biotin mol-
ecule linked via AAG spacer so that they could bind to NC membranes (1620215, Bio-Rad,
USA), which had been previously soaked with neutralite avidin (NLA) (NLA30, e-proteins,
Belgium) and dried at 50˚C. Lyophilised peptides were dissolved according to standard proto-
cols [38]. Where the solvent mixture in which the peptides were dissolved exhibited stable
background values, the peptide concentration was calculated based on their molar absor-
bances, measured either at 280 nm, for tyrosine (Y) and tryptophan (W) containing peptides
[39], or at 205 nm [40], for those without W or Y. For the remaining peptides, the concentra-
tion was calculated by dividing the peptide amount reported by the manufacturer by the vol-
ume of the solvent mixture in which they were dissolved.
Any promising candidate identified from the pilot peptide screening was synthesised with
higher purity grade (>90%) and with a N-terminal biotin—polyethylene glycol-glycine spacer
in order to improve water solubility as well as to increase rotation and ensure that the full
amino acid sequence could freely interact with Igs, as opposed to being adsorbed onto the
solid support and therefore unavailable for recognition by Ig [41].
Table 2. Information on the B-cell epitope prediction algorithms employed. A total of 80 peptides with high anti-
genic scores, independently predicted from four different B-cell prediction algorithms, were selected for synthesis. AA:
amino acid; AUC: area under the curve.
Algorithm Details n
ABCPred Predicts antigenic regions of fixed even length and assigns a score, ranging from zero to one, for
the whole predicted k-mer.
20
lbtope Scans all possible 15mers with one AA offset on all the submitted sequences. A numeric score as
well as the probability of correctnesses of each prediction are outputted.
20
EpiQuest-
B
Calculates individual scores per AA residue (AGR) and the final peptides scores are ranked by the
relative immunogenicity index, which corresponds to the curve (AUC) in a plot residue position
vs. AGR.
20
Bepipred Assigns a score for each AA residue on the submitted sequences. Predicted epitope regions can be
of any length� 1 AA with a score greater than the set cut-off (0.35 for default values). The
antigenicity of the 16mers was calculated from the AUC in a plot residue position vs. score.
20
Total 80
https://doi.org/10.1371/journal.pntd.0007353.t002
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Pilot screening of peptides using arrays
Array production. sciFLEXARRAYER (Scienion AG, Germany) with a PDC 70 piezo dis-
pense capillary (type 3 coating, P-2030/ S-6051, Scienion AG, Germany) was used to spot 7 nl
of the selected peptides at the required concentrations in multiple replicates onto NC mem-
branes previously soaked with NLA and dried at 50˚C. rK39 (RAG0061, Rekom Biotech,
Spain) and a whole L. donovani lysate, obtained as described in [29], were both spotted on the
diagonals as positive controls as well as for orientation purposes. As negative controls, we spot-
ted a peptide specific for T. cruzi [42]. All controls were spotted at 0.1 mg/ml. Arrays were
incubated overnight (ON) at 50˚C upon completion of the spotting, to be hybridised with
serum the next day.
Hybridisation with serum/ image acquisition. Peptide arrays were blocked with phos-
phate-buffered saline (PBS) + 3% bovine serum albumin (BSA) (PBSB) ON at 4˚C or for 2h at
room temperature (RT), followed by three 5 minute washes of PBS + 0.05% Tween 20 (PBST).
In order to assess the peptide recognition by sera from VL patients and NEHCs, separate
arrays were hybridised with pooled Sudanese serum samples positive for VL and with com-
mercial pooled NEHC sera (S1-100ML, EMD Millipore Corporation, USA), respectively,
diluted in PBST + 3% BSA (PBSTB), for 1h. After five 5 minute washes with PBST, they were
incubated with fluorescent mouse anti-Human IgG1 Fc—Alexa Fluor 488 antibody (AB) (A-
10631, ThermoFisher) diluted 1:1000 in PBSTB, for 1h at RT. Followed by five 5 minute
washes with PBST, the arrays were incubated at 50˚C until completely dry.
Images were acquired at 500ms and 20 dB gain with a digital CCD camera (ORCA-R2,
Hamamatsu, Japan) coupled to a fluorescence microscope (model BX53, Olympus, Germany)
equipped with filter cube U-FGFP (N271350, Olympus, Germany). The fluorescence of the
spots was quantified using the software cellSens Dimensions v.1.7 (Olympus GmbH,
Germany)
Adaptation to an RDT
RDTs were composed of a NC strip sensitised with NLA at 3.5 mg/ml and a conjugate pad,
impregnated with anti-human IgG1-specific antibody conjugated to 40nm gold beads (nanoQ,
Belgium). The strip was either housed within a plastic cassette, with a buffer application well
and a test/reading window (cassette), or not (dipstick). Prior to application on the RDT, equal
volumes of serum and the biotinylated peptide at stock concentration were mixed and incu-
bated at 37˚C for 15 minutes. 3.5 μl of the mix was then pipetted onto the sample application
zone, just above the top of the sample pad and at the bottom end of the NC strip. 150 μl of
buffer solution was dispensed into the buffer application well (cassette) or dipsticks were
dipped into a recipient vessel filled with same volume of running buffer. After 15 minute incu-
bation, a test was deemed valid if a clear red control band was present in line with the ‘C’, and
deemed positive if a second band was present in line with the ‘T’. If no band was visible at the
‘T’ and a clear control band at ‘C’ developed, then the test was deemed ‘negative’. Invalid tests
were assessed by the absence of the red control band ‘C’ or by any other clear migration
problem.
Statistical analysis
All statistical analyses were performed using the computing environment R [43]. The final
fluorescence of each spot on the peptide arrays (spot fluorescence) was expressed in arbitrary
units and calculated by subtracting the mean background value of a given acquired image
from the individual fluorescence values. Mean background value was calculated from the
mean of six-eight fluorescence measures in random positions on the arrays where no
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PLOS Neglected Tropical Diseases | https://doi.org/10.1371/journal.pntd.0007353 May 6, 2019 8 / 20
fluorescence signal was detected. The peptide specificity was expressed as 95% Fiellers confi-
dence intervals (CIs) of the ratio between the mean spot fluorescence of eight replicates from
the arrays hybridised with VL serum and that of arrays hybridised with NEHC serum (ratio
VL/NEHC). CIs were calculated with the mratios R package [44].
RDT results were compared with defined clinical status to establish sensitivity and 95% CIs
with Clopper-Pearson exact method using the PropCIs R package [45].
Results
MS of selected antigenic bands identified over 1300 hits
The development of the western blot strips immunoassayed with active Indian VL serum sam-
ples and relapsed patients revealed the protein bands detected by human IgG1. New gels were
run in order to get three selected antigenic bands (B1, B2 and B3) excised (Fig 2), to ultimately
have their constituent proteins revealed by MS. Criteria to select the antigenic bands were (I)
strong recognition, visually assessed by their intensity, (II) ubiquitous recognition i.e. recog-
nised by the majority of the patients and (III) confident match between the bands from the
western blots and the new gels.
A total of 1357 putative L. donovani proteins were identified from the three selected
antigenic bands, with some identified in multiple bands (redundant matches). All these candi-
date antigen proteins were submitted to the in silico filter (Fig 1) to reduce the number of
promising candidates while restricting to those possessing protein features that correlate with
antigenicity.
The in silico filter excluded over 90% of the uniquely identified proteins
The initial 1357 IDs from the three selected antigenic bands (Fig 2) contained 678 unique IDs
that matched the LdBPK v1 genome (we only matched the peptides identified by MS against
the LdBPK v1 genome, such that the analysis returned L. donovani protein hits only). Out of
these, 538 were considered to be constitutively expressed in both amastigote and promastigote
Fig 2. Gel and western blot strips immunoassayed with sera from Indian VL and EHC patients. The western blot
strips incubated with individual active VL sera revealed the L. donovani protein bands reacting with IgG1 from Indian
patients (VL WB). Three antigenic bands, B1, B2 and B3 were excised from gels to have their constituent proteins
identified by MS (Gel). The strips incubated with EHC sera did not develop any band (EHC WB). Molecular mass
markers are given in kDa.
https://doi.org/10.1371/journal.pntd.0007353.g002
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life stages following gene expression analysis, of which 209 had a MASCOT score� 100. Sixty
six of these candidates were found to be secretory, 60 of which as part of exosomes while 6
where actively secreted to the outside of the cell via the presence of a signal peptide. These 66
unique v1 IDs were merged with the corresponding IDs from the improved LdBPK v2 refer-
ence genome, making 62 annotated extracellular and constitutively expressed proteins, identi-
fied with confidence by MS, as shown in Fig 3.
Further three unique candidates harbouring TR domains were found to be constitutively
expressed and were identified with confidence by MS from the excised bands. Although none
of the three was found to be extracellular, they were kept for downstream epitope mapping as
such proteins containing TR domains are often B-cell antigens [46]. A single TR protein satis-
fying all the criteria described remained unannotated in the improved LdBPK v2 reference
genome. Results including the number of hits satisfying all the criteria applied are schemati-
cally shown in Fig 3 while the detailed list with all the 65 shortlisted proteins can be found in
S1 Table.
In silico selection of B-cell epitopes
All 65 shortlisted proteins were profiled with the B-cell prediction algorithms as detailed in the
methods section. Considering partially overlapping peptides, only that of highest score was
shortlisted. The top 20 scoring peptides, with no shared core sequences within a given algo-
rithm, were selected for synthesis, making a total of 80 high scoring peptides from four differ-
ent prediction algorithms, as shown in S2 Table.
Peptide antigenicity screening
Initial hybridisation revealed the most antigenic peptide. A first batch of peptide arrays
was produced in order to obtain insights about the reactivity of the peptides with human IgG1.
The visual inspection of the imaged arrays hybridised with both pooled serum groups (Suda-
nese VL and NEHC) diluted 1:100 revealed that a high number of peptides spotted at their
stock concentrations reacted with both serum pools (Fig 4).
Fig 3. Selected proteins for in silico epitope mapping. 65 proteins (‘Final 65 v2 IDs’) satisfied the criteria in either
branch shown in Fig 1 and were shortlisted to have their epitopes mapped with multiple in silico B-cell prediction
algorithms. In bold are the features added after each step of the filter.
https://doi.org/10.1371/journal.pntd.0007353.g003
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Hybridisation of the same batch of arrays with pooled serum at a higher dilution (1:200)
showed that a reduced number of peptides reacted with both serum groups, visually revealing
the most reactive peptide, as shown in Fig 5. Details of the most reactive peptide found, hence-
forth referred as EpQ11, are shown in Table 3.
Fig 4. Peptides reactivity with a pool of Sudanese VL and NEHC sera diluted at 1:100 showed to be unspecific.
[VL]: Section of an array hybridised with pooled Sudanese VL serum at 1:100 dilution. rk39 and a whole L.donovani
lysate (CLA) were spotted on the diagonal as positive controls as well as for orientation purposes. [NEHC]: the same
array section hybridised with a pool of NEHC sera at same dilution. The red circles indicate the spotting position of a
peptide specific for T. cruzi [42], employed here as negative control. Both images indicate the array section where the
peptide epitopes predicted from the lbtope algorithm were spotted.
https://doi.org/10.1371/journal.pntd.0007353.g004
Fig 5. Hybridisation of the peptide arrays with a pool of serum samples diluted 1:200 revealed the most sensitive
peptide. [VL]: Section of a peptide array hybridised with pooled Sudanese VL serum at 1:200 dilution. The most
reactive peptide (pep) was spotted in duplicates. rk39 and CLA spotting positions are shown. [NEHC]: the same array
hybridised with a pool of NEHC sera at same dilution. Both images are from the array section where the peptide
epitopes predicted from the EpiQuest algorithm were spotted.
https://doi.org/10.1371/journal.pntd.0007353.g005
Table 3. Information on the most antigenic peptide identified visually from the pilot screening with desalted peptides. Column ‘v2 ID’ and ‘v2 gene product’ refer to
the improved LdBPK reference genome.
Peptide ID Short ID Sequence AA residues v2 ID v2 gene product
EpQ_11_NIRI EpQ11 NIRIHLGDTIRIAPCK 82—97 LdBPK_360019900.1 Transitional endoplasmic reticulum ATPase, putative
https://doi.org/10.1371/journal.pntd.0007353.t003
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Specificity of peptide EpQ11 was highly concentration dependent. The most reactive
peptide from the initial pilot screening, EpQ11, was spotted at multiple concentrations in eight
replicates each onto a NC membrane pre-soaked and dried with NLA at 1 mg/ml and dried.
The hybridisation of two separate arrays with pooled serum samples diluted 1:200 showed that
the discrimination between the VL and the NEHC pooled sera was highly dependent on pep-
tide concentration, with the highest discrimination displayed when the peptide was spotted at
1.15 mg/ml, as shown in Fig 6.
Peptide EpQ11 bound specifically to IgG1 from VL patients in RDT prototypes. RDT
prototypes in two formats, cassettes and dipsticks, were tested with individual Sudanese VL
serum samples as well as NEHC from Europe, in order to confirm the specificity of the EpQ11
peptide in a point-of-care format. All of the NEHC sera (n = 10) were negative by both RDT
formats. Sensitivity values, assessed with VL serum samples (n = 19) varied between 79% (54—
94%) and 84% (60—97%) depending on the format tested (Table 4). Representative results for
these RDTs are shown in Fig 7.
Discussion
Identifying a biomarker of post-chemotherapeutic relapse remains a key element for VL con-
trol worldwide. The majority of relapses occur between 6 and 12 months after therapy
Fig 6. Peptide specificity for VL IgG1 was highly concentration dependent. Peptide EpQ11 was spotted at three
different concentrations in eight replicates each onto dry NC membranes, previously soaked with NLA. The highest
discrimination between VL and NEHC IgG1 (Ratio VL/NEHC) was obtained when the peptide was spotted at 1.15
mg/ml.
https://doi.org/10.1371/journal.pntd.0007353.g006
Table 4. EpQ11 performance in RDTs with Sudanese VL and NEHC patient sera. Summary of the RDT prototypes
tested with individual VL sera from Sudan or NEHC serum samples from Europe.
Serum Group n Format RDT results
Positive Negative
VL positive 19 Cassette 84,2% (16/19) 15.8% (3/19)
Dipstick 78.9% (15/19) 21.1% (4/19)
NEHC 10 Cassettea 0% (0/8) 100% (8/8)
Dipstick 0% (0/10) 100% (10/10)
a: 2/10 tests were deemed invalid (control line did not develop due to leakage of running buffer from the buffer
application well) and were therefore excluded from the sensitivity calculation.
https://doi.org/10.1371/journal.pntd.0007353.t004
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completion [47], while rates are drug dependant and can reach levels up to 20% at 12 months
after completion of therapy in immunocompetent patients [48]. The situation is even more
dramatic in HIV-coinfected patients, where relapse rates as high as 70% have been reported
[49]. Considering that most of the patients affected by VL live in poor and remote villages in
developing countries [50], the development of easy-to-use diagnostic tools is of utmost impor-
tance in order to follow up patients up to 12 months upon treatment completion in a primary
care setting. Currently there is no point-of-care serodiagnostic tool for detection of relapses in
VL. Despite unquestionable value of the rK39-based RDTs for active cases identification, they
cannot be used as a tool to detect relapses due to antibody persistence even after complete dis-
ease clearance [9–13].
We have identified a peptide detected by human IgG1 from VL patients by mapping epi-
topes from multiple proteins, which were selected from immunoblots by searching antigenic
features using comparative genomics and in silico algorithms. The peptide was adapted to
RDT prototypes and showed promising results for VL serology in terms of both sensitivity and
specificity with limited sample size. Given the free online availability and growing number of
various in silico algorithms to predict or scan multiple protein features from DNA or AA
sequences and the growing number of high quality sequenced genomes, the adopted strategy
can also be employed for the search of diagnostic biomarkers or vaccine candidates for other
infectious diseases [51, 52].
The decision to make use of comparative genomics and in silico algorithms to refine the
output from immunoblots came from the excessive number of putative hits identified by MS,
and we believe that the strength of our approach lies in this combination. Nonetheless, we con-
sider that technical issues might have been related to the excessive number of hits initially
identified by MS from the western blots. The immunogenic bands excised from the acrylamide
gels that were analysed by MS were excised from gels with wide lanes (59 mm). We believe
Fig 7. Peptide EpQ11 is specifically detected by Sudanese VL IgG1 in cassette as well as in dipstick format. ‘T’
indicates the location of the NLA at which, in a positive test, there is a red coloured line due to the presence of peptide-
IgG1 complex. Successful migration was ensured by the development of the control line at ‘C’.
https://doi.org/10.1371/journal.pntd.0007353.g007
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that excising such wide lanes from acrylamide gels contributed to the excessive number of hits:
by mechanically cutting along very wide lanes, we have probably included proteins that would
not have been present had we excised narrower (e.g. 4 mm wide) lanes, although multiple hits
would have been probably identified anyway.
We have identified antigens from L. donovani promastigotes due to ease of culturing. In the
host, promastigotes are phagocytosed by macrophages or other types of mononuclear phago-
cytic cells, where they differentiate into amastigotes, remaining in this form until transmission
to a new vector [53]. Therefore we believe that amastigote proteins are more likely to be tar-
geted by host Igs. We have chosen a non-stringent HAP cut-off for both promastigotes and
amastigotes (HAP>Q1) due to the generally nonstrong correlation between mRNA and pro-
tein expression levels observed in eukaryotes [54, 55]. By doing so, we avoided missing anti-
gens that might be constitutively expressed, despite low mRNA levels. Given the excessive
number of protein candidates identified by MS we could set a stricter MASCOT score cut-off,
ruling out proteins that could have been identified by chance in each antigenic band. Extracel-
lular proteins are more accessible for binding with host Igs, thus we have included this crite-
rion in our filter. Finally, because intracellular proteins harbouring TRs are amongst the most
widely used antigens for VL diagnosis [56], we decided to select such candidates in parallel to
extracellular proteins. Although the vast majority of epitopes founds in proteins are discontin-
uous [57], the use of such prediction algorithms is only meaningful in case the native 3D struc-
ture of the proteins is retained, which is not the case upon completion of an SDS-PAGE gel. In
addition, the prediction of discontinuous epitopes relies on the scarce availability of experi-
mentally validated epitopes.
Even though the in silico filter that we applied ruled out over 90% of the proteins initially
identified by MS from the immunoblots, it remained impracticable to test the antigenicity of
all 65 selected proteins. By screening synthetic peptides instead of recombinant proteins we
circumvented the lengthy and costly protein expression and purification steps and could there-
fore test a large number of top-scoring candidates predicted from multiple algorithms with
various prediction methods. Moreover, the production of peptide arrays allowed the screening
of multiple peptides at various concentrations using low volumes of reagents of limited avail-
ability to us (e.g. VL serum).
The pilot screening with peptide arrays revealed that the EpQ11 was the most sensitive pep-
tide, despite cross-reacting with NEHC serum (Fig 5). By showing the clear effect of the hybri-
disation conditions on the specificity of the EpQ11 in arrays, especially that of the spotting
concentration (Fig 6), we sought to test the EpQ11 in RDTs, taking into account that the for-
mat of the test (i.e. peptide array vs. RDTs) could have an even larger impact on the specificity/
sensitivity of the peptide. We believe that the long hybridisation periods employed in our pep-
tide arrays played a crucial role on the higher sensitivities observed when compared to the
RDT prototypes. On the other hand, by using a format of lower sensitivity, we managed to
avoid the false positive signals generated by the NEHC samples in peptide arrays. The intensity
of the test line of our RDT prototypes might be improved by using a larger peptide composed
of multiple copies in series (‘peptide trains’) or in parallel (multiple antigen peptides), a strat-
egy already used in vaccine development [58, 59], to boost the recognition of synthetic pep-
tides by Igs, although we are aware that this improvement in sensitivity might have a negative
effect on the specificity of the test.
In spite of these advantages of screening peptide epitopes in a high-throughput manner, the
most important antigens for VL diagnosis (e.g. rK39, rK28) are still recombinant proteins. It
would have been an interesting alternative to apply the in silico filter described here to proteins
of lower molecular weight (e.g. those between 25 and 37 kDa—Fig 2), to test the antigenicity of
a few of them. Low molecular weight proteins are generally easier to express and purify when
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compared to large antigens. We decided, however, to focus our search in predicted epitopes
from larger proteins due to (I) the large number of possible epitopes that proteins of high
molecular weight have and (II) we were not entirely convinced about the matching between
the antigenic bands in the western blots and those in the gels, mainly due to the high density of
proteins in that region of the gel (Fig 2).
Another limitation of our study lies in the restricted range of serum samples available to us.
Our ultimate goal was to use the EpQ11 peptide to detect IgG1 from pre-treatment VL patients
paired with post-treatment (deemed cured), such that we could assess its use as a replacement
for the Leishmania CLA in IgG1 RDTs, as described in [29]. Replacing the CLA by synthetic
peptides would allow the manufacturing of more robust RDTs as a non-invasive tool to help in
supporting the confirmation of cure after successful chemotherapy. Advantages of employing
synthetic peptides (vs. whole-cell lysates) include unproblematic and low-cost synthesis and
the production of more standardised (and potentially more sensitive and specific) diagnostic
tests. Due to local regulations, however, it is not possible to export human sera from India,
where the cured paired serum samples from our partner institutions are available (western
blots were carried out on site in 2015), such that we could only carry out the peptide pilot
screening as well as the sensitivity tests in RDTs with Sudanese active VL sera. As, however,
Sudanese patients show generally a weaker immune response when compared to Indian VL
patients [60], the serum samples that we tested can be considered ‘worst-case scenario’ samples
such that we would expect the sensitivity in India to be at least as high as the values reported in
this study (Table 4). The EpQ11 was also not tested with EHCs. However, EHCs used in both
western blots (Fig 2) and ELISAs were negative with L. donovani CLA [29]. Finally, even
though it is important to test the EpQ11 with serum samples from patients presenting with
potentially cross-reacting diseases (e.g. malaria, human African trypanosomiasis), we would
not expect a high rate of false positives due to low protein sequence conservation between the
LdBPK_360019900.1. and proteins from organisms causing potentially cross-reacting diseases,
especially in the region harbouring the EpQ11 sequence (Fig 8).
Our work was conducted as a proof of concept that comparative genomics and in silico
algorithms can be employed downstream of wet lab experiments for a rational search for diag-
nostic peptides. Further investigations, using a larger sample size of various clinical status,
including cured paired samples, EHCs as well as sera from patients presenting with potentially
cross-reacting diseases, are still required to confirm the potential of the EpQ11 (with possible
structural optimisations described above) as a stand-alone antigen for VL serodiagnosis.
Meanwhile, given the evidence from the present work that the described peptide specifically
Fig 8. The L. donovani protein containing the EpQ11 sequence shows low similarity to proteins from organisms
causing potentially cross-reacting diseases. The L. donovani protein harbouring the EpQ11 peptide
(LdBPK_360019900.1—v2 ID) was aligned against the proteome of organisms causing potentially cross-reacting
diseases with VL using MAFFT v7.222 [61]. Column 1: GenBank accession number; column 2: protein length
(position of first amino acid | position of last amino acid, 784 for LdBPK_360019900.1), column 3: alignment around
the region where the EpQ11 peptide is located. Numbers on top (470-560) indicate the alignment position. Screenshot
from belvu, SeqTools—4.44.1 [62] showing the most similar proteins to LdBPK_360019900.1.
https://doi.org/10.1371/journal.pntd.0007353.g008
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binds to IgG1 from Sudanese VL patient sera, the sequence of the EpQ11 could be synthetically
coupled to that of the rK39, potentially improving the sensitivity of the latter antigen, includ-
ing in IgG1 RDTs, whose potential in monitoring clinical status in VL has recently been
shown [63].
Conclusion
Based on the interpretation of the results of our experiments we conclude that:
1. Comparative genomics as well as in silico algorithms are useful tools for refining large out-
put from wet lab experiments for a rational search for diagnostic peptides.
2. B-cell epitopes prediction algorithms represent an interesting option for epitope mapping,
enabling the screening of peptides in a high-throughput manner with minimal reagent
consumption.
3. We have identified a peptide that specifically binds to human IgG1 from Sudanese VL
patients by refining wet lab experiments with in silico searches. Replacing the CLA by spe-
cific antigens would enable the manufacturing of more robust IgG1 RDTs for monitoring
clinical status in VL.
4. While further investigations are still required to confirm the potential of the EpQ11 peptide
as a stand-alone antigen for VL serodiagnosis, incorporation of its sequence into that of
rK39-based assays (i.e. rK39-EpQ11) might boost the sensitivity of this antigen in eastern
African patients as well as in IgG1 RDTs.
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